- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04453371
Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) (AtTAC)
Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS): A Multicentral Randomized Trial (AtTAC-trial)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
COVID 19 pandemic is a serious challenge for International medical community. There is lack of knowledge about the nature and character of the lung injury caused by this kind of infection. At the beginning COVID-associated lung injury was considered as typical ARDS, hence respiratory and nonrespiratory treatments were delivered according to general principles for this kind of illness. There is hypothesis that in predisposed individuals, alveolar viral damage is followed by an inflammatory reaction and by microvascular pulmonary thrombosis. This progressive endothelial thromboinflammatory syndrome may also involve the microvascular bed of the brain and other vital organs, leading to multiple organ failure and death. Understanding the crucial role of microthrombosis in the genesis of SARS-2-CoV led to a widespread anticoagulant use. Moreover, there is evidence about a possible benefit of thrombolysis in patients with severe COVID-19 pulmonary disease. For Instance, some investigators reported about three patients with COVID 19 lung injury treated with alteplase (tPA). Authors oversaw positive changes in P/F ratio in 3/3 patients, even if in two of these patients changes lasted for a short period. Another investigators reported about the improvements in alveolar ventilation, arterial oxygenation and diminishing in vasopressor's support in 4 patients with SARS-2CoV after thrombolysis. Encouraging results were obtained also by another team in case series of 5 patients who received alteplase. Thus, there is evidence suggesting that thrombolytic therapy may be beneficial when compared to standard care in patients with SARS-CoV-2 and severe respiratory failure. This hypothesis is based on a well-established pathophysiological concept of the occurrence of pulmonary damage as a result of microthrombosis of the lung vessels. Hence, it seems crucial to conduct a randomized clinical trial to test the effectiveness of this treatment.
Objective: To establish whether plasminogen activator (tPA) treatment improves alveolar ventilation P/F (PaO2/FiO2) ratio will be calculated each 6 hours during first 3 days after the end of thrombolysis procedure in patients with an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS).
Methods: Research assistants and/or clinician screen all mechanically ventilated patients for eligibility. Patients satisfying all of the Inclusion and Exclusion Criteria are classified as 'Eligible'. With informed consent from a substitute decision maker or under the decision of Concilium of three independent physicians, Eligible patients are 'Enrolled' into the study. Eligible patients Qualify for Randomization to one of the 2 groups: with or without thrombolytic therapy. In summary, patients are consented and Enrolled prior to Randomization. To enroll or randomize Eligible patients, research coordinators obtain informed consent and access the automated web-based system through Internet based program (available 24 hours/day). Each participating center has a separate computer-generated randomization schedule, with 1:1 (control to intervention) assignment, stratified by center, and using random variable block sizes.
The thrombolysis procedure: In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C. In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.
In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.
Statistical analysis: Primary data analysis will be based on intention to treat (ITT) analysis.
Data will be analyzed also on a modified ITT approach (mITT). Will be included in this analysis only patients with evidence of an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS).
Subgroups analysis: Some pre-defined subgroups analysis will be performed:
- Patients with with P/F <200 mmHg>100 mmHg;
- Patients with with P/F <100 mmHg;
- Patient 65+ group;
- Patients under 65 years old. Interim analyses: Interim analyses will not be performed
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe pulmonary coronavirus disease 19 (COVID 19) with suspect for MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome)
- P/F ratio <200 mmHg> 70 mmHg
a.) Contrast CT scan positive for pulmonary thrombosis, OR b.) Contrast CT scan negative for pulmonary thrombosis:
- D-Dimer > 10 mcg/mL, OR
- 5 < D-dimer < 10 mcg/mL and C Reactive Protein (CRP) > 100 mg/dL
Exclusion Criteria:
- Age < 18
- Pregnancy or breastfeeding
- Known allergy to iodinated contrast dye
- Severe vasoplegic shock: norepinephrine > 300 ng/kg*min
- Glomerular Filtration rate < 30 ml/min
- Active bleeding or absolute contraindication to anticoagulant therapy (Stroke (intracranial hemorrhage, hemorrhagic stroke), including a history of the last 6 months.; cancer of the Central nervous system and other localities with an increased risk of bleeding, vascular aneurysm, traumatic open heart massage, obstetric delivery, General operations, severe uncontrolled hypertension, gastric ulcer and 12-duodenal ulcer (for 3 months. from the moment of exacerbation), arterial or venous malformations, liver failure, liver cirrhosis, portal hypertension, esophageal varicose veins, active hepatitis).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study group
Thrombolysis
|
In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C. In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.
Other Names:
|
Placebo Comparator: Control group
Ringer's solution infusion
|
In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group. In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
P/F (PaO2/FiO2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ARDS caused by SARS-2-CoV.
Time Frame: Each 6 hours during first 3 days after the end of thrombolysis procedure.
|
Each 6 hours during first 3 days after the end of thrombolysis procedure.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilator-free time (days free from MV) for 28 days of observation.
Time Frame: 28 days
|
Calculated as 28 days - number of days when patient receive any kind of ventilatory support (MV + SV + NIV).
|
28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality in 28 days and 1 year after randomization despite of the reason.
Time Frame: 28 days, 1 year after randomization
|
28 days, 1 year after randomization
|
|
Length of stay in the ICU
Time Frame: 28 days
|
Number of days when patient was in ICU
|
28 days
|
Length of stay in hospital
Time Frame: 28 days
|
Number of days when patient was in hospital
|
28 days
|
The time needed for "improvement of 2 points" according to WHO "Ordinal Scale for Clinical Improvement"
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month
|
|
Chest radiographs on a daily basis and define barotrauma as the presence of new pneumothorax, pneumomediastinum, pneumoperitoneum, or subcutaneous emphysema.
Time Frame: Daily up to extubation than once a week/or on attending intensivist's discretion up to 1 month
|
Daily up to extubation than once a week/or on attending intensivist's discretion up to 1 month
|
|
Blood Pressure in millimetres of mercury
Time Frame: Each 4 hours during first 2 weeks after the end of thrombolysis procedure.
|
Each 4 hours during first 2 weeks after the end of thrombolysis procedure.
|
|
Heart Rate in beats per minute
Time Frame: Each 4 hours during first 2 weeks after the end of thrombolysis procedure.
|
Each 4 hours during first 2 weeks after the end of thrombolysis procedure.
|
|
Blood Oxygen Saturation
Time Frame: Each 4 hours during first 2 weeks after the end of thrombolysis procedure.
|
Each 4 hours during first 2 weeks after the end of thrombolysis procedure.
|
|
ECG Q-wave
Time Frame: Each 24 hours during first 2 weeks after the end of thrombolysis procedure.
|
Each 24 hours during first 2 weeks after the end of thrombolysis procedure.
|
|
ECG ST-segment
Time Frame: Each 24 hours during first 2 weeks after the end of thrombolysis procedure.
|
Each 24 hours during first 2 weeks after the end of thrombolysis procedure.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Tissue Plasminogen Activator
- Plasminogen
Other Study ID Numbers
- tPA-2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
China-Japan Friendship HospitalNot yet recruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
-
Dr. Behcet Uz Children's HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory Failure | Pediatric Acute Respiratory Distress Syndrome (PARDS)Turkey
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
-
Hospices Civils de LyonTerminatedAcute Respiratory Distress Syndrome (ARDS)France
Clinical Trials on Tissue plasminogen activator
-
University College, LondonRecruiting
-
University of California, San DiegoNational Institute of Neurological Disorders and Stroke (NINDS)CompletedStrokeUnited States
-
Washington University School of MedicineMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedVenous Thrombosis | Deep Vein Thrombosis | Postphlebitic Syndrome | Venous Thromboembolism | Post Thrombotic SyndromeUnited States
-
Beijing Tsinghua Chang Gung HospitalCompletedPulmonary Embolism | Acute Pulmonary EmbolismChina
-
Angde Biotech Pharmaceutical Co., Ltd.Unknown
-
Population Health Research InstituteHeart and Stroke Foundation of CanadaRecruitingMyocardial Infarction | Percutaneous Coronary InterventionCanada
-
Thomas Jefferson UniversityGenentech, Inc.Unknown
-
Penumbra Inc.Completed
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease